WO1994012632A1 - Improvements in nucleic acid synthesis by pcr - Google Patents

Improvements in nucleic acid synthesis by pcr Download PDF

Info

Publication number
WO1994012632A1
WO1994012632A1 PCT/GB1993/002436 GB9302436W WO9412632A1 WO 1994012632 A1 WO1994012632 A1 WO 1994012632A1 GB 9302436 W GB9302436 W GB 9302436W WO 9412632 A1 WO9412632 A1 WO 9412632A1
Authority
WO
WIPO (PCT)
Prior art keywords
primers
nucleic acid
length
chain
outermost
Prior art date
Application number
PCT/GB1993/002436
Other languages
French (fr)
Inventor
Chrisostomos Prodromou
Laurence Harris Pearl
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929224882A external-priority patent/GB9224882D0/en
Priority claimed from GB939307132A external-priority patent/GB9307132D0/en
Application filed by University College London filed Critical University College London
Publication of WO1994012632A1 publication Critical patent/WO1994012632A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Abstract

A method of synthesising nucleic acid by a polymerase chain reaction carried out on a series of overlapping primers which span the entire length of the nucleic acid to be synthesised, comprising two 5'-end outermost primers and inner primers therebetween, each of the outermost primers being present initially in a sufficient excess over each of the inner primers to select for chain-extension of the outermost primers and their chain-extension products, over inner primers and their chain-extension products, characterised in that: at least 6 primers are used; and the reaction is carried out continuously, without any intermediate step of separating nucleic acid molecules of shorter length than required for the total synthesis by PCR of substantially the full length nucleic acid.

Description

IMPROVEMENTS IN NUCLEIC ACID SYNTHESIS BY PCR
Background of the i nvention
1 . Fi e l d of the i nvention
This invention is the field of recombinant nucleic acid technology and more particularly relates to the polymerase chain reaction (PCR).
2. Description of the related art
The synthesis of even relatively short genes has generally been difficult and time-consuming. Both DNA strands are completely synthesised as short overlapping oligonucleotides which are phosphorylated, annealed and ligated to generate the full-length product (Edge e_i si. , 1981; Bell ≤± al., 1988; Ferretti ι si- , 1986). The cost of the synthesis can be reduced by synthesising oligonucleotides representing the partial sequence of each strand and the gaps in the annealed product 'filled in' using DNA polymerase prior to ligation (Rink et al., 1984). In practice, both these methods give a low yield of the full-length product and require amplification by cloning before any further manipulation of the synthesised gene. Recently, a PCR procedure has been described in which a 234 base oligonucleotide was chemically synthesised and primers used to amplify any full-length molecules that resulted from the chemical synthesis (Barnet and Erfle, 1990). However, the length of gene synthesisable is still relatively short. Sandhu et al. (1992) have described a method of synthesising DNA by PCR carried out on a series of 4 overlapping DNA molecules of alternating complementary strands which span the entire length of the DNA to be synthesised. Each of the 5'-end outermost DNA molecules (HI, H4) is present initially in a sufficient excess over each of the inner DNA molecules (H2, H3) to select for chain-extension of the outermost DNA molecules and their chain-extension products over inner DNA molecules and their chain-extension products. In a detailed example, HI to H4 are oligonucleotides of alternating complementary strands of lengths 86, 78, 63 and 17, with overlaps of 12-17 bp., and are used to make ds DNA 220 bp. long. The authors also suggest using four 100-mers with 15 bp overlaps to produce ds DNA of 355 bp. They further suggest that to construct a longer synthetic gene two 355-mers overlapping by 15 bp should be made in separate reactions and then subjected to a fresh PCR to yield a 695-mer.
The Sandhu £t si- method requires neither phosphorylation nor ligation and is relatively cheap as only oligonucleotides representing the partial sequence of each strand need to be chemically synthesised, as in the 'DNA-polymerase filling-in' method. However, it is a problem that the Sandhu e_£ si- method has a practical upper limit of about 355 bp for the DNA to be synthesised, this upper limit being dictated (a) by the fact that it is at present difficult to synthesise oligonucleotides of lengths exceeding 100 bases in reasonable yield and (b) by the need for 15 bp of overlap [(4 x 100) - (3 x 15) = 355] between each of the four oligonucleotides employed. While longer genes could be synthesised, this requires a second reaction. Summary of the invention It has now been found that Sandhu e_± si- method can be improved to enable longer nucleic acid molecules to be synthesised more easily. According to the present invention, the Sandhu et al . method is varied and improved by using at least 6 overlapping starting nucleic acid molecules, each of which can correspond to either strand of the nucleic acid molecule to be synthesised, and by carrying out the reaction continuously, without any intermediate step of separating nucleic acid molecules of shorter lengths than requireα for the total synthesis by PCR of substantially the full length nucleic acid. Preferably the full length nucleic acid thus synthesised exceeds 400, most preferably exceeds 500 bases or base-pairs in length.
In the following description, the starting nucleic acid molecules will be referred to as primers. Ordinarily they are oligonucleotides, a term which signifies tnat they are of relatively short length, for example less than 120 bases long, compared with the length of nucleic acid to be synthesised. The primers are mixed and subjected to PCR, so that their 3'-ends are extended to give longer double-stranded products. This is repeated for the double-stranded products until the full-sized nucleic acid is obtained. The full-length product is subsequently amplified by the 5'-end outermost oligonucleotides of each strand, which are present at a higher concentration than the inner ones and act as primers for the amplification. Brief description of the drawings
Fig.l is a schematic diagram of an embodiment of the method of the invention, explaining the chain-extension occurring;
Fig. 2 shows the oligonucleotides used in the synthesis of 522 bp long DNA encoding the lysozyme gene;
Fig. 3 is a photograph of a stained agarose gel showing that a full length gene of correct relative molecular mass has been synthesised by the method of the invention;
Fig. 4 is a schematic diagram which shows an embodiment of the invention in which the method is applied to plasmid DNA, enabling a gene to be synthesised directly into a plasmid.
Fig. 5 is a schematic diagram similar to that of Fig. 1, but showing another embodimentof the method of the invention using a different arrangement of primers; and
Fig. 6 is another schematic diagram, in briefer form, showing a further arrangement of primers. Description of the preferred embodiments A summary of particularly preferred features of the invention can be found in claims 2 onwards, the text of which should be regarded as part of the description also.
In the ordinary application of the invention the nucleic acid to be synthesised will be DNA and most usually a gene, i.e. a length of nucleic acid which comprises a region coding for a protein, preferably together with any associated sequences required or preferred for control of or aiding transcription or expression, e.g. a promoter region. However, the function of the nucleic acid to be synthesised is immaterial to the invention. It could be used, for example, to synthesise the intron DNA of a genome, which may be useful in gene therapy. There are no lower limits or known upper limits on the lengths of the nucleic acid to be synthesised. However, it is intended that the invention should be applied mainly to be synthesis of long lengths, e.g. exceeding 400, preferably exceeding 500 bases or base-pairs, since it is in such a context that its advantages are best employed. It will readily be possible to synthesise DNA of up to 1 kb(p) and even longer e.g. 2 or 5 kb(p). The upper limit will be dictated currently only by deviations of the conventional PCR technology from perfection, but currently would be unlikely to exceed 106 kb(p).
The initial product of the PCR method of invention is double-stranded nucleic acid, but if desired this could be made single-stranded (subject always to stability, avoiding looping back on itself etc.). Primers will normally be oligonucleotides, which will rarely exceed 100 bases in length. The 5'-end outermost primers can be provided by double-stranded nucleic acid having a protruding "sticky end" of single-stranded nucleic acid which has a 3'-terminus free. This single-stranded-nucleic acid serves as the primer, whereby the chain-extended molecule will contain the double-stranded-nucleic acid. This embodiment is illustrated later by reference to Fig. 4.
Although the invention is mainly of interest for PCR using wholly DNA primer and a DNA polymerase for chain extension, it is possible to apply it to reverse transcriptase PCT (RT-PCR), using mixed RNA and DNA primers, the outermost primers being of DNA, or even to wholly RNA primers using an RNA polymerase.
The operation of the invention is most easily seen from the simplified diagram of Fig. 1. The figure shows six stages o one, embodiment of the method, although these divisions are purely notional since synthesis is continuous, "in one pot". The first stage is the beginning of a reaction involving 10 overlapping oligonucleotides. The products at stage 2 have undergone one cycle, in which, for example, the left-hand, inner oligonucleotide marked "B" is extended from its 3'-end using the 5'-end outermost oligonucleotide "A" as template and likewise "A" is extended from its 3'-end using the inner oligonucleotide "B" as template. A hybrid (AB) is thus formed and separated into two complementary strands (AB1 , AB2). Other hybrids (CD etc.) are also formed and, after the denaturing step, separated into single strands (CD1, CD2 etc.), along all the length of the nucleic acid to be synthesised. Because the 5'-end outermost oligonucleotides (A, J) are in great excess over the inner oligonucleotides (B to I), the next cycle will result in increased amounts of AB hybrid, since primer A will be extended along the length of AB2 preferentially to primer C being extended along the length of CD2 and so on. (This preponderance is not shown in Figure 1). The nucleic acid synthesis proceeds in each cycle as shown until finally full length DNA is produced. This full length nucleic acid will also be amplified preferentially to any shorter nucleic acid requiring priming from an inner primer and so the process is self-selective for the full length product. Of course, the scheme shown in Fig. 1 is arbitrary in the sense that the intermediate hybrids formed are mixtures of (initially) AB, BC, CD, DE, EF, FG, GH, HI and IJ, followed by ABC, BCD, CDE and so on.
Complete synthesis of the nucleic acid results from the mutual extension of two halves which themselves result from the mutual extension of two halves etc. This is functionally identical to the technique of recursion in computer programming and we therefore describe this embodiment as 'Recursive PCR'.
A sophisticated development of the above embodiment of the invention is shown in Fig. 4. The outermost DNA molecules are plasmid DNA which has been cut. For ease of illustration, the outermost (A, J) and inner (B to I) primers are labelled correspondingly to Fig. 1. A and J are joined together as duplex (ds) DNA in the plasmid in the area between two sites, at which 3' and 5'-ends are marked. The 3'-end overlaps and is complementary to the 5'-end of B, while the 3'-end of J overlaps and is complementary to the 5'-end of I. ηe resultant full length molecules will be circular, and capable of transforming bacteria without further treatment. It is not necessary that successive inner primers be of alternate strands of the nucleic acid to be synthesised. So long as they are overlapping they can be of either or both strands. In the embodiment shown in Figure 5, for example, all the inner primers (L to R) are of the same strand. Of course, the outermost primers (K,S) have to be of different strands. Analogously to Figure 1, the reaction can be regarded as proceeding from the left-hand end via initial hybrids KLM1, KLM2, KLMO1, KLMO2 ... to the full length sequence KLMNOPQRS1, KLMNOPQRS2. After strand separation the primers K and S operate on the entire strand as template, priming in both directions, as for Fig. 1. Nine primers in all are shown in Figure 5, but it is immaterial whether the number is odd or even, and fewer or more primers than nine could be used according to the length of nucleic acid to be synthesised.
In Figure 6, which shows another possible arrangement, involving a total of 13 primers, one of the middle internal primers is of different strand from the others. The arbitrary stages, analogous to a mixture of those shown in Figures 1 and 5, have been omitted from Figure 6 for brevity.
The outermost primers are both 5'-ended. Any 3'-ended outermost primer having the sequence of a part of the nucleic acid to be synthesised lying beyond the outermost 5'-ends of the primers would simply not be copied and the full length DNA would extend only between the two 5'-outermost ends of the series of primers. In other words the nucleic acid to be synthesised is by definition, that which lies between the 5'-end outermost primers. However, the outermost primers may be double-stranded and this embodiment has some advantage, because polymerases can chew back the ends of the single-stranded primers. For instance, in one experiment in which the invention was applied to synthesising the 1044 bp ornithine carboxylase gene, using 18 primers, a 71-base outermost primer was chewed back by 8-bases and then began to prime on to innder primer No. 14 with which the chewed back sequence had 9 bp of perfect homology. The full range of ratios of the 5'-end outermost to inner DNA primers is not capable of definition by sharply defined numerical limits. On the one hand, a high ratio is very favourable because it will increase selection for full length products and molar ratios within the range 50-500:1, preferably 100-500:1, will be of particular importance. While higher ratios are usable, they will often imply such a low amount of inner primer that the PCR will not readily proceed. Such a consideration will be well understood by those skilled in the art. On the other hand, a molar excess of (say) only 10 times might well not work, depending, however, on the other variables such as lengths of overlaps in the series of primers, lengths of gaps to be filled in, the number and length of the primers, and the proof-reading accuracy of the polymerase or other chain-extending enzyme employed.
Successive primers (which mutually serve as "primer and template") will normally overlap, generally by a length predominantly within the range 15-25 bp, preferably 17-20 bp. This applies to the starting primers and to primers formed by the initial hybrids, e.g. KLM1 in Figure 5 which primes for further nucleic acid synthesis on the template provided by 0. Generally stated, usual "rules" for arranging priming conditions in the PCR apply. One such set of "rules" (for all DNA PCR) is to arrange for the overlapped region to have a melting temperature of 45-72°C, preferably 50-60°C, and most preferably 52-56°C. Melting temperature is roughly calculable by allowing 4°C for every G-C pairing and 2°C for every A-T pairing in the prospective duplex of the "overlapped region".
Preferably the proportion of G-C pairs in the overlapped region should not exceed 67% (two thirds) and it is preferred that it does not exceed 55% with less than 45% even more preferred.
Normally, the series of primers will not be abutting within a single prospective strand. That is, there will be gaps to be filled in by chain-extension. However, this rule is not critical and it is possible to use abutting molecules. Thus, fcr instance, in Figure 1, instead of primers E and G of the first strand, each overlapping F of the second strand, primers EX and G could be used instead, where X represents the sequence between the 3'-end of E and the 5'-end of G in Figure 1. The lengths of the gaps to be filled in can be varied widely, but assuming arbitrarily a primer length of from 50 to 100 and an overlap of 17-20 at each end thereof, they would usually be in the range 10 to 66. The preferred length of primer is arbitrary since there is a trade-off between the ease of oligonucleotide synthesis and the ease of performing this reaction, but will usually be in the 50 to 100 range, preferably predominantly 70 to 90.
It is preferred n&i to use T jj polymerase as the chain-extending enzyme in the PCR, because there are now available enzymes of superior proof-reading ability which are preferred. They include Vent, Deep Vent and Pfu DNA polymerases.
Otherwise the conditions are generally as for amplifying PCRs. The primers should not contain any undue complementarity with other primers, to avoid unwanted primer-primer interactions. If the DNA to be synthesised has any tendency for self-complementarity leading to looping, regions with this property should be split across two overlapping primers.
In general, cycling temperatures and times in the chain-extension, annealing and denaturing steps can be those conventionally used. It is preferred to anneal at a temperature not more than 10°C below the calculated melting temperature of the prospective duplex. The final chain extension step is preferably carried out at elevated temperatures, up to 72°C, for (say) 10 minutes, to ensure completion of the reaction. The following Example illustrates the invention. Example MATERIALS AND METHODS
Ten oligonucleotide primers, representing a synthetic human-lysozyme gene sequence were synthesized using β-cyanoethyl phosphoramidite chemistry and purified on polyacrylamide gels by British Biotechnology Limited Figure 2 shows these primers in the conventional left to right = 5'-end to 3'-end manner. Their sequences are shown in SEQ ID NO: 1 to 10 hereinafter. The oligonucleotide primers were 54-86 bases long to minimise errors and obtain good yields in the chemical synthesis. The overlapping regions 17-20 bp in length, were designed to give melting temperatures mainly in the range 52-56°C, but in some instances up to 60°C to ensure good primer specificity and a similar degree of annealing at all overlaps in the initial cycles of the PCR reaction. A computer search of both strands of the entire sequence with the sequences of each of the overlap regions showed them to be unique and unlikely to give non-specific priming. Subsequent insertion of the synthesised gene into expression vectors, was facilitated by the incorporation in the outermost oligonucleotide primers, of an EcoRI site at the 5' end and a Hlndlll site at the 3' end of the gene. A Shine-Dalgarno sequence and the T0 transcription terminator (from gene 10B of bacteriophage T7) were incorporated into the outermost 5' and 3' oligonucleotide primers, respectively, for the efficient expression of the gene in Escherichia co i . Sequences such as the T0 transcription terminator can potentially inhibit the PCR reaction by formation of strong stem loops. This was prevented by incorporating the two halves of the stem loop in separate overlapping oligonucleotide primers (see Figure 2). In addition to the EcoRI and Hindlll sites, fourteen additional unique restriction sites were incorporated into the gene sequence to aid subsequent sub-cloning and utagenesis (see Figure 2). The coding region was designed to contain the most frequently used codons found in highly expressed genes in Saccharomvces cerevisiae. an intended expression host, except where this conflicted with the unique restriction sites. As the codon usage of E. col i is not as biased as that of S. cerevisiae. the use of optimal S. cerevisiae codon usage will still allow efficient expression in E. coli .
The PCR reaction (30 cycles of: 2 min at 95°C, 2 min at 56°C and 1 min at 72°C, with a final 10 min at 72°C) was performed in a Techne PHC-2 thermal cycler. The annealing temperature of 56°C was chosen to minimise non-specific priming by the overlapping oligonucleotides, (see above). The reaction contained 20 - 30 pmoles of the outermost 5' oligonucleotides of each strand, 2 - 3, 0.2 - 0.3, or 0.02 - 0.03, pmoles of the internal oligonucleotides, 10 μl 10 X Vent-buffer, 4 U Vent DNA-poly erase (New England Biolabs), and 6 μl 100 M MgS04, in a total reaction volume of 100 μl overlaid with 50 μl paraffin oil to prevent evaporation. The full-sized PCR product (522 bp) was isolated from a 1.5% low-melting-point agarose gel, purified by sequential extraction with phenol, phenol/chloroform, chloroform and ether, ethanol precipitated and finally 200 ng of the purified PCR product digested in a total volume of 20 μl containing 1 U EcoRI. 1 U HindlH (Northumbria Biochemical s Ltd.) and 2 μl 10 X buffer. The restriction enzymes were extracted with Strataclene resin (Stratagene) . The DNA was ethanol-precipitated and ligated to 200 ng of similarly digested phagemid, pGEM3Zf(+) (Promega), in a total volume of 20 μl , containing 0.5 U T4 DNA ligase (Northumbria Biochemical s Ltd.) and 2 μl 10 X buffer. E. coli DH5a was transformed and plated onto LB plates containing ampici 11 in (100 mg/ml ) , X-gal (20 mg/ml) and IPTG (32 mg/ml). Double-stranded phagemid was sequenced by the dideoxy-chain-termination method (Sanger et al . , 1977) using Sequenase (Tabor and Richardson, 1987). RESULTS AND DISCUSSION
We have used the method of the invention to synthesise a human lysozyme gene of 522 bp using 10 overlapping oligonucleotides in a single reaction. To our knowledge, this is the largest double-stranded DNA molecule to be synthesised to date, in a single step.
Figure 3 shows a photograph of a stained agarose gel. Lanes 1-3 correspond to the three molar ratios of 5:-outermost: inner oligonucleotide primers used, i.e. 10:1, 100:1 and 1000:1 lane 4 shows markers. The lysozyme gene synthesised is arrowed. It is likely that the inner oligonucleotide primers, which can only be extended in the normal 5' to 3' direction, are inhibitory to the synthesis of the full-length product (Figure 3. lane 1). However, at internal oligonucleotide primer concentrations 100 times lower than that of the outer oligonucleotide primers (2 - 3 pmoles/μl) efficient and selective synthesis of the full-length product is obtained (Lane 2). Compare the marker of relative molecular mass 514 base pairs in lane 4. At inner oligonucleotide primer concentrations 1000 times lower than those of the outermost oligonucleotide primers, no visible amplification was observed. This is ascribed to use of too small an amount of the inner oligonucleotide primers (lane 3).
REFERENCES
Barnet.R.W. and Erfle.H. (1990) Nucleic Acids Res., 18, 3094.
Bell.L.D., Smith, .C., Derbyshire,R. , Finlay.M., Johnson,I., Gilbert,R., Slocombe,P., Cook,E., Richards,H., Clissold.P.,
Meredith,D., Powel l-Jones,C.H. , Dawson,K.M., Carter,B.L. and
McCullagh.K.G. (1988) Gene, 63, 155-163.
Edge,M.D., Greene,A.R., Heathcl iffe.G.R. , Meacock.P.A. , Schuch.W.,
Scanlon, D.B., Atkinson,T.C. , Newton,C.R. and Markham.A.F. (1981) Nature, 292, 756-762.
Ferretti.L., Karnik,S.S., Khorana.H.G. , Nassal,M. and Oprian.D.D.
(1986) Proc.Natl.Acad.Scl.USA, 83, 599-603.
Mead,D.A., Pey.N.K., Herrnstadt.C. , Marcil.R.A. and Smith,L.M.
(1991) Biotechnology, 9, 657-663. Rink,H., Manfred,L., Sieber.P. and Meyer,F. (1984) Nucleic Acids
Res., 15, 6369-6387.
Sandhu,G.S., Aleff.R.A. and Kline,B.C. (1992) Biotechniques, 12,
14-16.
Sanger.F., Nicklen.S. and Coulsen.A.R. (1977) Proc.Natl.Acad.Scl.USA, 74, 5463-5467.
Tabor,S. and Richardson,C.C. (1987) Proc.Natl .Acad.Sci .USA,
84,4767-4771.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: UNIVERSITY COLLEGE LONDON
(B) STREET: Gower Street
(C) CITY: London
(E) COUNTRY: GB
(F) POSTAL CODE (ZIP): WC1E 6BT
(A) NAME: PEARL, Laurence Harris
(B) STREET: 24 Hurst Street, Herne Hill
(C) CITY: London
(E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP): SE24 OEG
(A) NAME: PRODROMOU, C risostomos
(B) STREET: 18 Dewsgreen, Vange
(C) CITY: Basildon
(D) STATE: Essex
(E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP): SS16 4NT
(ii) TITLE OF INVENTION: IMPROVEMENTS IN NUCLEIC ACID SYNTHESIS BY PCR (iii) NUMBER OF SEQUENCES: 10
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
(v) CURRENT APPLICATION DATA:
APPLICATION NUMBER: WO Not yet assigned (vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: GB 9224882.2
(B) FILING DATE: 27-NOV-1992
(vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: GB 9307132.2
(B) FILING DATE: 06-APR-1993
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 77 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
SUBSTITUTESHEET (iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Oligo primer for synthesis of lysozyme gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: GCCGGAATTC AAATAATTTG TTTAACTTTA AGGAGATCTA CATATGAAGG TTTTCGAAAG 60 ATGTGAGCTC GCTAGAA 77
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 81 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(v) FRAGMENT TYPE: N-terminal
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Oligo primer for synthesis of lysozyme gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: CCAAACACAT CCAGTTAGCC AAAGAGATAC CACGGTACCC GTCCATACCC AATCTCTTCA 60 AGGTTCTAGC GAGCTCACAT C 81
(2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 86 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Oligo primer for synthesis of lysozyme gene
SUBSTITUTESHEET (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
GCTAACTGGA TGTGTTTGGC TAAGTGGGAA TCTGGTTACA ACACTCGAGC TACCAACTAC 60
AACGCTGGTG ACAGGTCGAC CGACTA 86 (2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 81 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Oligo primer for synthesis of lysozyme gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: TTAACGGCGC CTGGGGTCTT ACCGTCGTTA CACCAGTATC TAGAATTAAT TTGGAAGATA 60 CCGTAGTCGG TCGACCTGTC A 81
(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 68 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Oligo primer for synthesis of lysozyme gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: GACCCCAGGC GCCGTTAACG CTTGTCACTT GTCTTGTTCT GCTTTGCTGC AGGACAACAT 60 CGCTGACG 68
(2) INFORMATION FOR SEQ ID NO: 6:
SUBSTITUTESHEET (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Oligo primer for synthesis of lysozyme gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: CCTTGTGGGT CTCTAACAAC GCGTTTAGCA CAAGCAACAG CGTCAGCGAT GTTGTCCT 58 (2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 55 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Oligo primer for synthesis of lysozyme gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: TGTTAGAGAC CCACAAGGTA TCAGAGCTTG GGTTGCTTGG AGAAATCGAT GTCAA 55
(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 68 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Oligo primer for synthesis of lysozyme gene
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
SUBSTITUTESHEET TCCTTACTAA ACACCACAAC CTTGAACGTA TTGTCTGACG TCTCTGTTTT GACATCGATT 60 TCTCCAAG 68
(2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: CDNA
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Oligo primer for synthesis of lysozyme gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: GTTGTGGTGT TTAGTAAGGA TCCTCTAGAA TAACCCCTTG GGGCCTCTAA ACGGGTCTTG 60
(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 54 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Oligo primer for synthesis of lysozyme gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: CCGATGCCGA AGCTTCCTCC ATGGAGCAAA AACCCCTCAA GACCCGTTTA GAGG 54
SUBSTITUTE SHEET

Claims

1. A method of synthesising nucleic acid by a polymerase chain reaction carried out on a series of overlapping primers which span the entire length of the nucleic acid to be synthesised, comprising two 5'-end outermost primers and inner primers therebetween, each of the outermost primers being present initially in a sufficient excess over each of the inner primers to select for chain-extension of the outermost primers and their chain-extension products, over inner primers and their chain-extension products, characterised in that: at least 6 primers are used; and the reaction is carried out continuously, without any intermediate step of separating nucleic acid molecules of shorter length than required for the total synthesis by PCR of substantially the full length nucleic acid.
2. A method according to claim 1, characterised in that the initial molar ratio of 5' end outermost to inner primers is at least 100:1
3. A method according to claim 2, characterised in that the ratio is from 100:1 to 500:1.
4. A method according to any preceding claim characterised in that nucleic acid of length exceeding 400 bases or base-pairs is synthesised.
5. A method according to claim 4 characterised in that nucleic acid of length 500 to 5000 bases or base-pairs is synthesised.
6. A method according to any preceding claim characterised in that the primers are of alternating complementary strands.
7. A method according to any preceding claim, characterised in that the primers are wholly of DNA.
8. A method according to claim 7 characterised in that the series of primers provides a prospective ds DNA sequence having gaps within each prospective strand to be rilled in by chain extension and in that these gaps are from 10 to 66 bases in length.
9. A method according to claim 7 or 8, characterised in that all the primers are arranged to have or impart an overlap of from 17-20 bp calculated to impart a melting temperature to the hybrid in the area of overlap of from 50 to 60°C, said melting temperature being calculated by allowing 4°C for each G-C pairing and 2°C for each A-T pairing, provided that G-C pairings do not exceed 67%.
10. A method according to claim 7, 8, or 9, characterised in that it is carried out using a chain-extending enzyme of superior proof-reading ability to I&jj polymerase.
PCT/GB1993/002436 1992-11-27 1993-11-26 Improvements in nucleic acid synthesis by pcr WO1994012632A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929224882A GB9224882D0 (en) 1992-11-27 1992-11-27 Improvements in dna synthesis by pcr
GB9224882.2 1992-11-27
GB9307132.2 1993-04-06
GB939307132A GB9307132D0 (en) 1993-04-06 1993-04-06 Improvements in nucleic acid synthesis by pcr

Publications (1)

Publication Number Publication Date
WO1994012632A1 true WO1994012632A1 (en) 1994-06-09

Family

ID=26302055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/002436 WO1994012632A1 (en) 1992-11-27 1993-11-26 Improvements in nucleic acid synthesis by pcr

Country Status (1)

Country Link
WO (1) WO1994012632A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010063A1 (en) * 1996-09-03 1998-03-12 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive dna
WO1998032845A1 (en) * 1997-01-24 1998-07-30 Bioinvent International Ab A method for in vitro molecular evolution of protein function
WO1999010358A2 (en) * 1997-08-22 1999-03-04 Peter Hegemann Method for producing nucleic acid polymers
WO1999014318A1 (en) * 1997-09-16 1999-03-25 Board Of Regents, The University Of Texas System Method for the complete chemical synthesis and assembly of genes and genomes
WO2000049142A1 (en) * 1999-02-19 2000-08-24 Febit Ferrarius Biotechnology Gmbh Method for producing polymers
WO2001007645A2 (en) * 1999-07-22 2001-02-01 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Method for marking solid, liquid and gaseous substances
EP1149905A1 (en) * 1996-12-18 2001-10-31 Maxygen, Inc. Methods and compositions for polypeptide engineering
WO2001085929A2 (en) * 2000-05-08 2001-11-15 Genencor International, Inc. Methods for forming recombined nucleic acids
WO2002038769A2 (en) * 2000-11-09 2002-05-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Dna sequences, which code for optimised eukaryotic hpv 16-l1 and hpv 16-l2
WO2002081490A2 (en) * 2001-01-19 2002-10-17 Egea Biosciences, Inc. Computer-directed assembly of a polynucleotide encoding a target polypeptide
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
WO2007068068A2 (en) * 2005-12-12 2007-06-21 União Brasileira De Educacão E Assistência - Sponsor Of Da Pucrs Method for the obtainment of chimeric nucleotide sequences and chimeric nucleotide sequences
US7262031B2 (en) 2003-05-22 2007-08-28 The Regents Of The University Of California Method for producing a synthetic gene or other DNA sequence
WO2008022789A2 (en) 2006-08-23 2008-02-28 Febit Holding Gmbh Programmable oligonucleotide synthesis
WO2008115632A2 (en) * 2007-02-09 2008-09-25 The Regents Of The University Of California Method for recombining dna sequences and compositions related thereto
US7662551B2 (en) 2000-12-22 2010-02-16 Alligator Bioscience Ab Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
US7737088B1 (en) 1998-08-28 2010-06-15 Febit Holding Gmbh Method and device for producing biochemical reaction supporting materials
WO2010094772A1 (en) 2009-02-20 2010-08-26 Febit Holding Gmbh Synthesis of sequence-verified nucleic acids
WO2016057951A3 (en) * 2014-10-09 2016-06-02 Life Technologies Corporation Crispr oligonucleotides and gene editing
GB2619548A (en) * 2022-06-10 2023-12-13 Nunabio Ltd Nucleic acid and gene synthesis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316018A2 (en) * 1985-03-29 1989-05-17 Cetus Oncology Corporation Modification of DNA sequences
EP0385410A2 (en) * 1989-02-28 1990-09-05 Canon Kabushiki Kaisha Partially double-stranded oligonucleotide and method for forming oligonucleotide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316018A2 (en) * 1985-03-29 1989-05-17 Cetus Oncology Corporation Modification of DNA sequences
EP0385410A2 (en) * 1989-02-28 1990-09-05 Canon Kabushiki Kaisha Partially double-stranded oligonucleotide and method for forming oligonucleotide

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Gene synthesis: Assembly of target sequences using mutually priming long oligonucleotides", CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 1989, WILEY & SONS, INC.,US;, pages 8.2.8 - 8.2.13 *
C. PRODROMOU AND L.H. PEARL: "Precursive PCR: a novel technique for total gene synthesis", PROTEIN ENGENEERING, vol. 5, no. 8, December 1992 (1992-12-01), IRL PRESS OXFORD, ENGL., pages 827 - 829, XP002176276 *
G.S. SANDHU ET AL.: "Dual asymmetric PCR: One-step construction of synthetic genes", BIOTECHNIQUES, vol. 12, no. 1, January 1992 (1992-01-01), EATON PUBL. CO., MA,US;, pages 14 - 16, XP002216325 *
M.A. WOSNICK ET AL.: "Total chemical synthesis and expression in Escherichia coli of a maize glutathione-transferase (GST) gene", GENE, vol. 76, no. 1, 1989, ELSEVIER PUBLISHERS, N.Y., U.S.;, pages 153 - 160, XP023543510, DOI: doi:10.1016/0378-1119(89)90017-6 *
R.M. HORTON ET AL.: "Engeneering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension", GENE, vol. 77, no. 1, 1989, ELSEVIER PUBLISHERS, N.Y., U.S.;, pages 61 - 68 *

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830713A (en) * 1986-11-04 1998-11-03 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
WO1998010063A1 (en) * 1996-09-03 1998-03-12 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive dna
EP1231269A1 (en) * 1996-12-18 2002-08-14 Maxygen, Inc. Methods and compositions for polypeptide engineering
EP2202308A3 (en) * 1996-12-18 2011-11-30 Codexis Mayflower Holdings, LLC Methods and compositions for polypeptide engineering
EP1149905A1 (en) * 1996-12-18 2001-10-31 Maxygen, Inc. Methods and compositions for polypeptide engineering
WO1998032845A1 (en) * 1997-01-24 1998-07-30 Bioinvent International Ab A method for in vitro molecular evolution of protein function
US7432083B2 (en) 1997-01-24 2008-10-07 Bioinvent International Ab Method for in vitro molecular evolution of protein function
US6989250B2 (en) 1997-01-24 2006-01-24 Bioinvent International Ab Method for in vitro molecular evolution of protein function
EP1352959A1 (en) * 1997-01-24 2003-10-15 Bioinvent International AB A method for in vitro molecular evolution of protein function
WO1999010358A2 (en) * 1997-08-22 1999-03-04 Peter Hegemann Method for producing nucleic acid polymers
WO1999010358A3 (en) * 1997-08-22 1999-08-05 Peter Hegemann Method for producing nucleic acid polymers
EP1538206A2 (en) 1997-09-16 2005-06-08 Egea Biosciences, LLC Method for the complete chemical synthesis and assembly of genes and genomes
EP1538206A3 (en) * 1997-09-16 2008-03-05 Egea Biosciences, LLC Method for the complete chemical synthesis and assembly of genes and genomes
US6521427B1 (en) 1997-09-16 2003-02-18 Egea Biosciences, Inc. Method for the complete chemical synthesis and assembly of genes and genomes
WO1999014318A1 (en) * 1997-09-16 1999-03-25 Board Of Regents, The University Of Texas System Method for the complete chemical synthesis and assembly of genes and genomes
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US7737088B1 (en) 1998-08-28 2010-06-15 Febit Holding Gmbh Method and device for producing biochemical reaction supporting materials
WO2000049142A1 (en) * 1999-02-19 2000-08-24 Febit Ferrarius Biotechnology Gmbh Method for producing polymers
US9568839B2 (en) 1999-02-19 2017-02-14 Synthetic Genomics, Inc. Method for producing polymers
US7790369B2 (en) 1999-02-19 2010-09-07 Febit Holding Gmbh Method for producing polymers
US6586211B1 (en) 1999-02-19 2003-07-01 Febit Ferrarius Biotechnology Gmbh Method for producing polymers
EP1728860A1 (en) * 1999-02-19 2006-12-06 febit biotech GmbH Method for producing polymers
WO2001007645A3 (en) * 1999-07-22 2001-06-07 November Ag Molekulare Medizin Method for marking solid, liquid and gaseous substances
WO2001007645A2 (en) * 1999-07-22 2001-02-01 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Method for marking solid, liquid and gaseous substances
US7037726B2 (en) 2000-05-08 2006-05-02 Genencor International, Inc. Methods for forming recombined nucleic acids
WO2001085929A2 (en) * 2000-05-08 2001-11-15 Genencor International, Inc. Methods for forming recombined nucleic acids
US6534292B1 (en) 2000-05-08 2003-03-18 Genencor International, Inc. Methods for forming recombined nucleic acids
WO2001085929A3 (en) * 2000-05-08 2002-03-21 Genencor Int Methods for forming recombined nucleic acids
WO2002038769A2 (en) * 2000-11-09 2002-05-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Dna sequences, which code for optimised eukaryotic hpv 16-l1 and hpv 16-l2
WO2002038769A3 (en) * 2000-11-09 2003-01-09 Deutsches Krebsforsch Dna sequences, which code for optimised eukaryotic hpv 16-l1 and hpv 16-l2
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7662551B2 (en) 2000-12-22 2010-02-16 Alligator Bioscience Ab Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
WO2002081490A3 (en) * 2001-01-19 2003-11-27 Egea Biosciences Inc Computer-directed assembly of a polynucleotide encoding a target polypeptide
US7966338B2 (en) 2001-01-19 2011-06-21 Johnson & Johnson Computer-directed assembly of a polynucleotide encoding a target polypeptide
WO2002081490A2 (en) * 2001-01-19 2002-10-17 Egea Biosciences, Inc. Computer-directed assembly of a polynucleotide encoding a target polypeptide
US7262031B2 (en) 2003-05-22 2007-08-28 The Regents Of The University Of California Method for producing a synthetic gene or other DNA sequence
WO2007068068A3 (en) * 2005-12-12 2007-08-02 Ubea Method for the obtainment of chimeric nucleotide sequences and chimeric nucleotide sequences
WO2007068068A2 (en) * 2005-12-12 2007-06-21 União Brasileira De Educacão E Assistência - Sponsor Of Da Pucrs Method for the obtainment of chimeric nucleotide sequences and chimeric nucleotide sequences
WO2008022789A2 (en) 2006-08-23 2008-02-28 Febit Holding Gmbh Programmable oligonucleotide synthesis
EP2489671A2 (en) 2006-08-23 2012-08-22 febit holding GmbH Programmable oligonucleotide synthesis
WO2008115632A2 (en) * 2007-02-09 2008-09-25 The Regents Of The University Of California Method for recombining dna sequences and compositions related thereto
WO2008115632A3 (en) * 2007-02-09 2008-11-06 Univ California Method for recombining dna sequences and compositions related thereto
WO2010094772A1 (en) 2009-02-20 2010-08-26 Febit Holding Gmbh Synthesis of sequence-verified nucleic acids
WO2016057951A3 (en) * 2014-10-09 2016-06-02 Life Technologies Corporation Crispr oligonucleotides and gene editing
CN107002078A (en) * 2014-10-09 2017-08-01 生命技术公司 CRISPR oligonucleotides and gene editing
US9879283B2 (en) 2014-10-09 2018-01-30 Life Technologies Corporation CRISPR oligonucleotides and gene editing
GB2619548A (en) * 2022-06-10 2023-12-13 Nunabio Ltd Nucleic acid and gene synthesis

Similar Documents

Publication Publication Date Title
WO1994012632A1 (en) Improvements in nucleic acid synthesis by pcr
US5023171A (en) Method for gene splicing by overlap extension using the polymerase chain reaction
Prodromou et al. Recursive PCR: a novel technique for total gene synthesis
US6228999B1 (en) Nucleic acid indexing
US5629179A (en) Method and kit for making CDNA library
ES2336433T3 (en) MODIFIED MOLDS THROUGH GENETIC ENGINEERING AND ITS USE IN AMPLIFICATION OF UNIQUE CEBADOR.
AU632760B2 (en) Rna and dna amplification techniques
US5132215A (en) Method of making double-stranded dna sequences
US6110710A (en) Sequence modification of oligonucleotide primers to manipulate non-templated nucleotide addition
AU3798393A (en) Exchangeable template reaction
WO1998040518A9 (en) Nucleic acid indexing
AU2004305055B2 (en) Engineered templates and their use in single primer amplification
WO1991007506A1 (en) A method of synthesizing double-stranded dna molecules
WO2000020639A1 (en) Enzymatic synthesis of oligonucleotide tags
JPH05508313A (en) Polynucleotide amplification
JPH06153952A (en) Method for pretreatment for carrying out amplifying and labeling of unknown double-stranded dna molecule in trace amount
AU2002254773B2 (en) Novel methods of directed evolution
KR101503726B1 (en) Primer capable of controlling its activity by DNA restriction enzyme, method for amplifying a gene using the same, and method for designing the primer
WO1992013104A1 (en) 5' and 3' polymerase chain reaction walking from known dna sequences
AU710779B2 (en) Sequence modification of oligonucleotide primers to manipulate non-templated nucleotide addition
CN115605590A (en) Method for preparing site-directed modified long-chain DNA
EP1130092A1 (en) A method of preparing recombinant nucleic acids
JP2024510046A (en) Unbiased simultaneous amplification method for preparing double-stranded DNA libraries from multiple types of nucleic acid samples
CN113832147A (en) Efficient PCR primer for large-fragment DNA synthesis and amplification, method and application
JP2020054239A (en) Method for producing double-stranded DNA fragment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase